In an effort to overcome pricing pressures and bounce back from patent losses, Germany’s second-largest drugmaker has unloaded assets and reshuffled its management team.
After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.
So, heard anything lately about Valeant? Yeah. Even by the standards of an industry under siege, Valeant experienced quite the tumultuous last year or so.